Remsima and Inflectra: new infliximab 'biosimilars'

Remsima and Inflectra are the first biosimilar monoclonal antibodies to become available in the UK.

Remsima and Inflectra have the same indications and dosing as Remicade, and are supplied in the same pharmaceutical form and strength.
Remsima and Inflectra have the same indications and dosing as Remicade, and are supplied in the same pharmaceutical form and strength.

Biosimilar medicines are so called because they have been specifically developed to be highly similar to an existing biologic medicine, in this case the anti-tumour necrosis factor (anti-TNF) antibody Remicade (infliximab).

Further information
View Remsima drug record
View Inflectra drug record
Questions about biosimilar versions of infliximab

Remsima and Inflectra are licensed for the same indications as Remicade: rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriatic arthritis and psoriasis.

Clinical trials have shown that there are no clinically meaningful differences in quality, efficacy or safety between Remsima/Inflectra and Remicade.

Both Remsima and Inflectra are available at an NHS list price of £377.66 per 100mg vial.

 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more